CN109400663A - 金丝小枣中提取环磷酸腺苷的方法及在预防癌症上的应用 - Google Patents
金丝小枣中提取环磷酸腺苷的方法及在预防癌症上的应用 Download PDFInfo
- Publication number
- CN109400663A CN109400663A CN201811379610.1A CN201811379610A CN109400663A CN 109400663 A CN109400663 A CN 109400663A CN 201811379610 A CN201811379610 A CN 201811379610A CN 109400663 A CN109400663 A CN 109400663A
- Authority
- CN
- China
- Prior art keywords
- jujube
- adenosine monophosphate
- cyclic adenosine
- golden
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 13
- 240000008866 Ziziphus nummularia Species 0.000 title 1
- 241001247821 Ziziphus Species 0.000 claims abstract description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 10
- 239000002002 slurry Substances 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 9
- 238000009833 condensation Methods 0.000 claims abstract description 8
- 230000005494 condensation Effects 0.000 claims abstract description 8
- 230000008569 process Effects 0.000 claims abstract description 6
- 238000010992 reflux Methods 0.000 claims abstract description 6
- 108010059892 Cellulase Proteins 0.000 claims abstract description 5
- 229940106157 cellulase Drugs 0.000 claims abstract description 5
- 238000004140 cleaning Methods 0.000 claims abstract description 5
- 239000012535 impurity Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 4
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 4
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 abstract description 3
- 238000006911 enzymatic reaction Methods 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 230000004083 survival effect Effects 0.000 abstract description 2
- 210000000107 myocyte Anatomy 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- -1 carrotene Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了金丝小枣中提取环磷酸腺苷的方法及在预防癌症上的应用,包括以下步骤:步骤1,将新鲜的金丝小枣清洗除杂后去皮、去核,微波烘干后研磨成粉,得到枣粉;步骤2,枣粉与软化水按重量比1:(7~9)混合,搅拌15min,得到枣浆液;步骤3,向枣浆液中加入纤维素酶,控制pH,酶解1‑2h,得到酶解液;步骤4,将酶解液经过冷凝,冷凝温度控制在35℃‑55℃,得到残渣;步骤5,残渣用乙醇回流法提取,得到金丝小枣环磷酸腺苷提取液。本发明终止酶反应后经过冷凝再提取细胞内的环磷酸腺苷,平衡温度,提高环磷酸腺苷的提取率,提取得到的环磷酸腺苷,可以提高心肌细胞存活并预防癌症发生,在预防癌症方面有重要价值。
Description
技术领域
本发明属于生物技术领域,具体地说,涉及金丝小枣中提取环磷酸腺苷的方法及在预防癌症上的应用。
背景技术
金丝小枣是我国枣资源中品质极其优良的品种之一,国内外享有较高的声誉。金丝小枣含有丰富的蛋白质、脂肪、碳水化合物、粗纤维、钙、铁、钾、镁、胡萝卜素、硫胺素、核黄素、维生素A、C、P、果酸等多种营养成份。医学研究证明,金丝小枣对贫血、高血压、动脉硬化、急慢性肝炎和肝硬化患者的血清转氨酶增高等均有很好的疗效。金丝小枣还有造血不可缺少的营养素。三萜类化合物,有较强的抑制癌细胞的作用。经常食用金丝小枣,具有抗胃肠道、肝脏恶性肿瘤的作用。提取金丝小枣中的环磷酸腺苷对预防与治疗癌症具有重大意义,目前,浓缩提取的比例并不高。
有鉴于此特提出本发明。
发明内容
本发明要解决的技术问题在于克服现有技术的不足,提供金丝小枣中提取环磷酸腺苷的方法及在预防癌症上的应用,为解决上述技术问题,本发明采用技术方案的基本构思是:
金丝小枣中提取环磷酸腺苷的方法,包括以下步骤:
步骤1,将新鲜的金丝小枣清洗除杂后去皮、去核,微波烘干后研磨成粉,得到枣粉;
步骤2,枣粉与软化水按重量比1:(7~9)混合,搅拌15min,得到枣浆液;
步骤3,向枣浆液中加入纤维素酶,控制pH,酶解1-2h,得到酶解液;
步骤4,将酶解液经过冷凝,冷凝温度控制在35℃-55℃,得到残渣;
步骤5,残渣用乙醇回流法提取,得到金丝小枣环磷酸腺苷提取液。
进一步地,所述步骤1中微波烘干的温度控制在80℃左右,低温慢烘干,时间控制在25-40min。
进一步地,步骤3中pH控制在4-6。
进一步地,步骤3中酶解的温度为40℃左右。
采用上述技术方案后,本发明与现有技术相比具有以下有益效果。
一种预防癌症的药剂,包含上述方法提取的金丝小枣环磷酸腺苷提取液。
本发明终止酶反应后经过冷凝再提取细胞内的环磷酸腺苷,平衡温度,消除酶抑制剂等试剂和温度变化对细胞内环磷酸腺苷含量的影响,提高环磷酸腺苷的提取率,同时控制酶解的次数,降低成本,有效提高提取效率,提取得到的环磷酸腺苷,可以提高心肌细胞存活并预防癌症发生,在预防癌症方面有重要价值。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面对实施例中的技术方案进行清楚、完整地描述,以下实施例用于说明本发明,但不用来限制本发明的范围。若非特指,所有的份、百分比均为重量单位。
实施例1
金丝小枣中提取环磷酸腺苷的方法,包括以下步骤:
步骤1,将新鲜的金丝小枣清洗除杂后去皮、去核,微波烘干后研磨成粉,微波烘干的温度控制在80℃左右,低温慢烘干,时间控制在25-40min,研磨成粉得到枣粉;
步骤2,枣粉与软化水按重量比1:7混合,搅拌15min,得到枣浆液;
步骤3,向枣浆液中加入纤维素酶,pH控制在4-6,酶解的温度为40℃左右,酶解1h,得到酶解液;
步骤4,将酶解液经过冷凝,冷凝温度控制在35℃-55℃,得到残渣;其中,冷凝可采用蒸馏塔方法。
步骤5,残渣用乙醇回流法提取,得到金丝小枣环磷酸腺苷提取液。乙醇回流法提取已是公知技术,这里不再赘述,也可以采用其它提取方式提取。
实施例2
金丝小枣中提取环磷酸腺苷的方法,包括以下步骤:
步骤1,将新鲜的金丝小枣清洗除杂后去皮、去核,微波烘干后研磨成粉,微波烘干的温度控制在80℃左右,低温慢烘干,时间控制在25-40min,研磨成粉得到枣粉;
步骤2,枣粉与软化水按重量比1:9混合,搅拌15min,得到枣浆液;
步骤3,向枣浆液中加入纤维素酶,pH控制在4-6,酶解的温度为40℃左右,酶解1h,得到酶解液;
步骤4,将酶解液经过蒸馏塔冷凝,冷凝温度控制在35℃-55℃,得到残渣;
步骤5,残渣用乙醇回流法提取,得到金丝小枣环磷酸腺苷提取液。
实施例3
一种预防癌症的药剂,包含上述实施例1或2提取的金丝小枣环磷酸腺苷提取液。可以是针剂、胶囊等,只要应用本发明方法提取物制备得到的药剂,皆可实现预防癌症的作用。
以上所述仅是本发明的较佳实施例而已,并非对本发明作任何形式上的限制,虽然本发明已以较佳实施例揭露如上,然而并非用以限定本发明,任何熟悉本专利的技术人员在不脱离本发明技术方案范围内,当可利用上述提示的技术内容作出些许更动或修饰为等同变化的等效实施例,但凡是未脱离本发明技术方案的内容,依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与修饰,均仍属于本发明方案的范围内。
Claims (5)
1.金丝小枣中提取环磷酸腺苷的方法,其特征在于,包括以下步骤:
步骤1,将新鲜的金丝小枣清洗除杂后去皮、去核,微波烘干后研磨成粉,得到枣粉;
步骤2,枣粉与软化水按重量比1:(7~9)混合,搅拌15min,得到枣浆液;
步骤3,向枣浆液中加入纤维素酶,控制pH,酶解1-2h,得到酶解液;
步骤4,将酶解液经过冷凝,冷凝温度控制在35℃-55℃,得到残渣;
步骤5,残渣用乙醇回流法提取,得到金丝小枣环磷酸腺苷提取液。
2.根据权利要求1所述的金丝小枣中提取环磷酸腺苷的方法,其特征在于,所述步骤1中微波烘干的温度控制在80℃左右,低温慢烘干,时间控制在25-40min。
3.根据权利要求1所述的金丝小枣中提取环磷酸腺苷的方法,其特征在于,所述步骤3中pH控制在4-6。
4.根据权利要求1所述的金丝小枣中提取环磷酸腺苷的方法,其特征在于,所述步骤3中酶解的温度为40℃左右。
5.一种预防癌症的药剂,其特征在于,包含权利要求1-4任一所述方法提取的金丝小枣环磷酸腺苷提取液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811379610.1A CN109400663A (zh) | 2018-11-20 | 2018-11-20 | 金丝小枣中提取环磷酸腺苷的方法及在预防癌症上的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811379610.1A CN109400663A (zh) | 2018-11-20 | 2018-11-20 | 金丝小枣中提取环磷酸腺苷的方法及在预防癌症上的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109400663A true CN109400663A (zh) | 2019-03-01 |
Family
ID=65474256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811379610.1A Pending CN109400663A (zh) | 2018-11-20 | 2018-11-20 | 金丝小枣中提取环磷酸腺苷的方法及在预防癌症上的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109400663A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116262772A (zh) * | 2021-12-14 | 2023-06-16 | 无棣县华龙食品有限公司 | 一种水-醇双相萃取红枣渣中cAMP的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101643491A (zh) * | 2009-09-07 | 2010-02-10 | 河南农业大学 | 一种提取枣中环磷酸腺苷的方法 |
CN101899080A (zh) * | 2010-01-28 | 2010-12-01 | 山东鼎力枣业食品集团有限公司 | 金丝小枣环磷酸腺苷生产方法 |
NZ585793A (en) * | 2007-11-30 | 2012-06-29 | Chi Yu Fen | Compositions comprising a ginsenoside, a glycyrrhizically related acid and a jujuba cyclic adenosine monophosphate for treating depression and anxiety |
CN103467553A (zh) * | 2013-09-23 | 2013-12-25 | 山西天骄生物集团有限公司 | 一种从枣皮中高效提取cAMP的方法 |
-
2018
- 2018-11-20 CN CN201811379610.1A patent/CN109400663A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ585793A (en) * | 2007-11-30 | 2012-06-29 | Chi Yu Fen | Compositions comprising a ginsenoside, a glycyrrhizically related acid and a jujuba cyclic adenosine monophosphate for treating depression and anxiety |
CN101643491A (zh) * | 2009-09-07 | 2010-02-10 | 河南农业大学 | 一种提取枣中环磷酸腺苷的方法 |
CN101899080A (zh) * | 2010-01-28 | 2010-12-01 | 山东鼎力枣业食品集团有限公司 | 金丝小枣环磷酸腺苷生产方法 |
CN103467553A (zh) * | 2013-09-23 | 2013-12-25 | 山西天骄生物集团有限公司 | 一种从枣皮中高效提取cAMP的方法 |
Non-Patent Citations (3)
Title |
---|
关荣发 等: "《食品加工基础》", 30 April 2016, 吉林大学出版社 * |
许牡丹 等: "超声波辅助酶法提取木枣环磷酸腺苷的工艺条件优化", 《食品科技》 * |
魏强华 等: "《食品生物化学与应用》", 31 July 2015, 重庆大学出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116262772A (zh) * | 2021-12-14 | 2023-06-16 | 无棣县华龙食品有限公司 | 一种水-醇双相萃取红枣渣中cAMP的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104211827B (zh) | 一种从猴头菇菌渣中提取多糖的方法 | |
CN101560260A (zh) | 一种提取灵芝菌丝体胞内多糖的工艺和方法 | |
CN101283760A (zh) | 从桃渣中提取制备膳食纤维的方法 | |
CN107653055B (zh) | 一种超声辅助水酶法提取茶叶籽油的方法 | |
CN101525363A (zh) | 从红枣中提取环磷酸腺苷(cAMP)的方法 | |
CN101560264A (zh) | 一种提取金针菇菌丝体胞内多糖的工艺组合及其确定方法 | |
CN101560262A (zh) | 一种提取猴头菇菌丝体胞内多糖的工艺组合及其确定方法 | |
CN109576324A (zh) | 一种黄芪多糖及其生物提取法 | |
CN109400663A (zh) | 金丝小枣中提取环磷酸腺苷的方法及在预防癌症上的应用 | |
CN106319017A (zh) | 一种富含人参皂苷rh2的发酵物的制备方法 | |
CN103088089A (zh) | 一种阿卡波糖的发酵方法 | |
CN106832021A (zh) | 一种肉桂渣粗多糖的制备方法 | |
CN118575957B (zh) | 一种细胞营养补充剂及其制备方法 | |
CN108004015A (zh) | 一种盐地碱蓬籽油超临界二氧化碳提取工艺 | |
CN113564094B (zh) | 一种提高桑黄胞内多酚积累量的方法 | |
CN106892994A (zh) | 一种蓝莓渣粗多糖的制备方法 | |
CN112931650A (zh) | 一种红茶菌及其制备方法 | |
CN104357527B (zh) | 一种微生物发酵法从茶籽粕中提取茶皂素的方法 | |
CN106748776A (zh) | 蒲公英绿原酸用的酶解水提法 | |
CN106832032A (zh) | 一种提取银耳多糖和银耳蛋白的方法 | |
AU2020102037A4 (en) | A method of efficiently increasing the alpha-glucosidase inhibitor content in fresh mulberry leaves by the solid-state fermentation | |
CN102191297A (zh) | 一种松茸多糖的制作方法 | |
CN102876756B (zh) | 一种低聚木糖联产乳酸的工艺 | |
CN101720816A (zh) | 一种含灵芝有效成分酸奶的制作方法 | |
CN109007810A (zh) | 三酶一酵功能养生食品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190301 |